Diagnostic and prognostic value of RUNX1 in ovarian serous cystadenocarcinoma and its role in cancer progression via suppressing ferroptosis
By: Deng He, Yu Zhou, Tiantian Feng, Hu Wang, Nenghuan Tang, Shangqi Ni, Wang Xi and Chengju Zhang
References
- Rickards J, Brooks BA, Rivera-Betancourt A, Velasquez D. A rare case of low-grade serous cystadenocarcinoma of the ovary in a seventeen-year-old woman. Cureus. 2022; 14(8): e28086.
- Sun Z, Zhou R, Dai J, Chen J, Liu Y, Wang M, Zhou R, Liu F, Zhang Q, Xu Y, et al. KRT19 is a promising prognostic biomarker and associates with immune infiltrates in serous ovarian cystadenocarcinoma. Int J Gen Med. 2023; 16: 4849–4862.
- Adlekha S, Chadha T. Malignant mixed epithelial tumour of ovary-serous papillary cystadenocarcinoma and transitional cell carcinoma with tubo-ovarian torsion: A rare tumour with rare presentation. Malays J Med Sci. 2013; 20(5): 79–82.
- Takagi Y, Hatori T, Itano O, Shinoda M, Kato A, Nitori N, Kato F, Kato A, Nakao A, Tamura T, et al. Pancreatic serous cystadenocarcinoma diagnosed with liver metastasis at 7 years after the resection of the primary serous neoplastic lesion. Clin J Gastroenterol. 2022; 15(2): 505–512.
- Shen D, Wu C, Chen M, Zhou Z, Li H, Tong X, Chen Z, Guo Y. Prognosis prediction and drug guidance of ovarian serous cystadenocarcinoma through mitochondria gene-based model. Cancer Genet. 2025; 292–293: 1–13.
- Zhang J, Li Y, Fan TY, Liu D, Zou WD, Li H, Li YK. Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma. Front Oncol. 2022; 12: 1021558.
- Zhang J, Ouyang D, Liu M, Xiang Y, Li Z. Research progress on ferroptosis and PARP inhibitors in ovarian cancer: Action mechanisms and resistance mechanisms. Front Pharmacol. 2025; 16: 1598279.
- Kapper C, Oppelt P, Arbeithuber B, Gyunesh AA, Vilusic I, Stelzl P, Rezk-Fureder M. Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance. Life Sci. 2024; 349: 122720.
- Niu C, Jiang D, Guo Y, Wang Z, Sun Q, Wang X, Ling W, An X, Ji C, Li S, et al. Spermidine suppresses oxidative stress and ferroptosis by Nrf2/HO-1/GPX4 and Akt/FHC/ACSL4 pathway to alleviate ovarian damage. Life Sci. 2023; 332: 122109.
- Zheng X, Jin X, Ye F, Liu X, Yu B, Li Z, Zhao T, Chen W, Liu X, Di C, et al. Ferroptosis: A novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy. Exp Hematol Oncol. 2023; 12(1): 65.
- She X, Lan B, Tian H, Tang B. Cross talk between ferroptosis and cerebral ischemia. Front Neurosci. 2020; 14: 776.
- Feng Q, Hao S, Fang P, Zhang P, Sheng X. Role of GPX4 inhibition-mediated ferroptosis in the chemoresistance of ovarian cancer to taxol in vitro. Mol Biol Rep. 2023; 50(12): 10189–10198.
- Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019; 575(7784): 688–692.
- Zhan S, Yung MMH, Siu MKY, Jiao P, Ngan HYS, Chan DW, Chan KKL. New insights into ferroptosis initiating therapies (FIT) by targeting the rewired lipid metabolism in ovarian cancer peritoneal metastases. Int J Mol Sci. 2022; 23(23): 15263.
- Zou T, Huang S, Xie R, Liu J. The Nrf2/GPX4 antioxidant pathway suppresses ferroptosis to protect against hearing impairment in cochlear ischemia-reperfusion injury. Int Immunopharmacol. 2025; 167: 115655.
- Ma DY, Liu JX, Wang LD, Zhi XY, Luo L, Zhao JY, Qin Y. GSK-3beta-dependent Nrf2 antioxidant response modulates ferroptosis of lens epithelial cells in age-related cataract. Free Radic Biol Med. 2023; 204: 161–176.
- Chen J, Wu W, Wang L, Zhang J, Che X, Zhai L, Zhao Z, Li Y. TYMS enhances colorectal cell antioxidant capacity via the KEAP1-NRF2 pathway to resist ferroptosis. J Cancer. 2025; 16(2): 417–429.
- Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018; 173(2): 400–416.e11.
- Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation. 2021; 2(3): 100141.
- Yu G, Wang LG, Han Y, He QY. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS: J Integr Biol. 2012; 16(5): 284–287.
- Chen Z, Zhang M, Lu Y, Ding T, Liu Z, Liu Y, Zhou Z, Wang L. Overexpressed lncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX/miR4429/UBE2C axis. Oncol Rep. 2022; 48(3): 1–5.
- Ardil B, Alper M. Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell. Naunyn-Schmiedebergs Arch Pharmacol. 2022; 395(9): 1109–1123.
- Hu X, He Y, Han Z, Liu W, Liu D, Zhang X, Chen L, Qi L, Chen L, Luo Y, et al. PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma. Cell Death Dis. 2022; 13(11): 1010.
- Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: A novel approach to reversing drug resistance. Mol Cancer. 2022; 21(1): 47.
- Pekarek L, Garrido-Gil MJ, Sanchez-Cendra A, Cassinello J, Pekarek T, Fraile-Martinez O, Garcia-Montero C, Lopez-Gonzalez L, Rios-Parra A, Alvarez-Mon M, et al. Emerging histological and serological biomarkers in oral squamous cell carcinoma: Applications in diagnosis, prognosis evaluation and personalized therapeutics (Review). Oncol Rep. 2023; 50(6): 213.
- Xie B, Chen X, Zhao L. SNORA71C promotes development and metastasis of breast cancer by regulating RUNX1 and ferroptosis. MedComm, 2023; 4(3): e262.
- Chang Z, Liu B, He H, Li X, Shi H. High expression of RUNX1 in colorectal cancer subtype accelerates malignancy by inhibiting HMGCR. Pharmacol Res. 2024; 206: 107293.
- Janta S, Pranweerapaiboon K, Vivithanaporn P, Plubrukarn A, Chairoungdua A, Prasertsuksri P, Apisawetakan S, Chaithirayanon K. Holothurin A inhibits RUNX1-enhanced EMT in metastasis prostate cancer via the Akt/JNK and P38 MAPK signaling pathway. Mar Drugs. 2023; 21(6): 345.
- Ariffin NS. Increased RUNX1 mutations in breast cancer disease progression. Pathol Res Pract. 2024; 254: 155076.
- Doffo J, Bamopoulos SA, Kose H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, et al. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci U S A. 2022; 119(9): e2105691119.
- Zheng LL, Cai L, Zhang XQ, Lei Z, Yi CS, Liu XD, Yang JG. Dysregulated RUNX1 predicts poor prognosis by mediating epithelialmesenchymal transition in cervical cancer. Curr Med Sci. 2022; 42(6): 1285–1296.
- Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De Keersmaecker K, Sole X, Xu L, Paietta E, et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med (N York, NY, U S). 2012; 18(3): 436–440.
- Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Gerritsen M, van der Meer LT, Williams O, Hoogerbrugge PM, Scheijen B, van Leeuwen FN. Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1. Exp Hematol. 2018; 60: 57–62.e53.
- Farina NH, Scalia S, Adams CE, Hong D, Fritz AJ, Messier TL, Balatti V, Veneziano D, Lian JB, Croce CM, et al. Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer. J Cell Physiol. 2020; 235(6): 5318–5327.
- Zhuang M, Gao W, Xu J, Wang P, Shu Y. The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. Biochem Biophys Res Commun. 2014; 448(3): 315–322.
- Wang S, Wang Y, Li Q, Zeng K, Li X, Feng X. RUNX1-IT1 favors breast cancer carcinogenesis through regulation of IGF2BP1/GPX4 axis. Discov Oncol. 2023; 14(1): 42.
- Li S, Li F, Xu L, Liu X, Zhu X, Gao W, Shen X. TLR2 agonist promotes myeloid-derived suppressor cell polarization via RUNX1 in hepatocellular carcinoma. Int Immunopharmacol. 2022; 111: 109168.
- Shakya A, McKee NW, Dodson M, Chapman E, Zhang DD. Anti-ferroptotic effects of Nrf2: Beyond the antioxidant response. Mol Cell. 2023; 46(3): 165–175.
- Zhang N, Li J, Zhang R, Chen H, He F, Li F, He Z, Liu X, Cheng L, Zhong F, et al. The STING-OLA1-Keap1-Nrf2 axis regulates ferroptosis in premature ovarian failure. Int J Biol Macromol. 2025; 337(Pt 1): 149424.
- Yuan C, Liu R, Xu X, Sun J, Zhu Y, Lu R, Liu Y, Chen J. Curcumin induces ferroptosis in hepatocellular carcinoma by regulating PERK/Nrf2/HO-1 signaling pathway. Transl Cancer Res. 2025; 14(11): 7641–7653.
- Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD, Musselman-Brown A, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017; 35(4): 314–316.
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12): 550.
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26(1): 139–140.
DOI: https://doi.org/10.2478/ahem-2026-0003 | Journal eISSN: 1732-2693
Language: English
Page range: 17 - 29
Submitted on: Aug 15, 2025
Accepted on: Feb 2, 2026
Published on: Mar 2, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2026 Deng He, Yu Zhou, Tiantian Feng, Hu Wang, Nenghuan Tang, Shangqi Ni, Wang Xi, Chengju Zhang, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.